title: [Clinical efficiency of tanshinone IIA-sulfonate in treatment of liver fibrosis of advanced schistosomiasis].
abstract: OBJECTIVE
  To evaluate the clinical efficiency of tanshinone IIA-sulfonate (STS) in the treatment of liver fibrosis of advanced schistosomiasis.
  
  
  METHODS
  A total of 73 advanced schistosomiasis patients were selected into a treatment group and 55 cases of advanced schistosomiasis were selected into a control group, and dipstick dye immunoassay assay (DDIA) for schistosomiasis and HBsAg of all the patients were negative. The patients in the treatment group received STS for 14 days, and all the patients in both groups received the conventional liver-protecting treatment for 14 days. All the patients in both groups received the measurements of portal vein, 4 indicators of liver fibrosis (P III P, C IV, HA, LN), and 3 indicators of serum enzyme activities (ALT, AST, gamma-GT).
  
  
  RESULTS
  After the treatments, the inside diameters of the portal vein and the degrees of the positive results of indicators of serum enzyme activities of all the patients of both groups decreased, but there were no statistically significant differences compared with those before the treatment. In the treatment group, the degrees of the positive results of indicators of liver fibrosis decreased somewhat, but there were no statistically significant differences compared with those before the treatment except C IV. In the control group, the degrees of the positive results of indicators of liver fibrosis fluctuated. In the treatment group, the indicator of liver fibrosis, CIV improved and the 2 indicators of liver fibrosis, PIIIP and HA improved significantly, but the indicators of serum enzyme activities did not improve.
  
  
  CONCLUSIONS
  STS is effective in the treatment of liver fibrosis of advanced schistosomiasis.
authors.affiliation: Third People's Hospital of Kunshan, Kunshan 215316, Jiangsu, China.
authors.forename: Xue-Hua
authors.initials: XH
authors.lastname: Niu
authors.forename: Hai-Yong
authors.initials: HY
authors.lastname: Hua
authors.forename: Wen-Jian
authors.initials: WJ
authors.lastname: Guo
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhang
authors.forename: Min
authors.initials: M
authors.lastname: Liu
authors.forename: Ye
authors.initials: Y
authors.lastname: Hong
authors.forename: Peng-Fei
authors.initials: PF
authors.lastname: Wu
authors.forename: Ping
authors.initials: P
authors.lastname: Lu
authors.forename: Hai-Fang
authors.initials: HF
authors.lastname: Zhang
mesh_terms: D000818:Animals; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000469:parasitology*; D008297:Male; D008875:Middle Aged; D010616:Phenanthrenes / Q000627:therapeutic use*; D012547:Schistosoma / Q000187:drug effects; D012552:Schistosomiasis / Q000188:drug therapy* / Q000469:parasitology*
chemical_list: D004365:Drugs, Chinese Herbal; D010616:Phenanthrenes; C024894:tanshinone II A sodium sulfonate